ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors by Zaika, Alex I. et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/09/765/16 $5.00
Volume 196, Number 6, September 16, 2002 765–780
http://www.jem.org/cgi/doi/10.1084/jem.20020179
 
765
 
 
 
Np73, A Dominant-Negative Inhibitor of Wild-type p53 
and TAp73, Is Up-regulated in Human Tumors
 
Alex I. Zaika,
 
1 
 
Neda Slade,
 
1 
 
Susan H. Erster,
 
1 
 
Christine Sansome,
 
1
 
Troy W. Joseph,
 
1 
 
Michael Pearl,
 
2 
 
Eva Chalas,
 
2 
 
and Ute M. Moll
 
1
 
1
 
Department of Pathology and 
 
2
 
Department of Obstetrics and Gynecology, Stony Brook University, Stony Brook, 
NY 11794
 
Abstract
 
p73 has significant homology to p53. However, tumor-associated up-regulation of p73 and ge-
netic data from human tumors and p73-deficient mice exclude a classical Knudson-type tumor
suppressor role. We report that the human TP73 gene generates an NH
 
2 
 
terminally truncated
isoform. 
 
 
 
Np73 derives from an alternative promoter in intron 3 and lacks the transactivation
domain of full-length TAp73. 
 
 
 
Np73 is frequently overexpressed in a variety of human can-
cers, but not in normal tissues. 
 
 
 
Np73 acts as a potent transdominant inhibitor of wild-type
p53 and transactivation-competent TAp73. 
 
 
 
Np73 efficiently counteracts transactivation func-
tion, apoptosis, and growth suppression mediated by wild-type p53 and TAp73, and confers
drug resistance to wild-type p53 harboring tumor cells. Conversely, down-regulation of en-
dogenous 
 
 
 
Np73 levels by antisense methods alleviates its suppressive action and enhances
p53- and TAp73-mediated apoptosis. 
 
 
 
Np73 is complexed with wild-type p53, as demon-
strated by coimmunoprecipitation from cultured cells and primary tumors. Thus, 
 
 
 
Np73 me-
diates a novel inactivation mechanism of p53 and TAp73 via a dominant-negative family net-
work. Deregulated expression of 
 
 
 
Np73 can bestow oncogenic activity upon the TP73 gene
by functionally inactivating the suppressor action of p53 and TAp73. This trait might be se-
lected for in human cancers. 
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Introduction
 
The p53 family member p73 has significant homology to
the p53 tumor suppressor. Human full-length p73 (TAp73)
shares 63% amino acid identity with the DNA-binding re-
gion of TP53 including conservation of all DNA contact
residues, as well as 38 and 29% identity with the tetramer-
ization domain and transactivation domain, respectively
(1). TAp73 also shows functional homology to p53. Ectop-
ically overexpressed TAp73
 
  
 
and TAp73
 
  
 
(two COOH-
terminal splice variants) largely mimic p53 activities, in-
cluding the induction of apoptosis, cell cycle arrest, and the
transactivation of an overlapping set of target genes (2, 3).
Moreover, endogenous TAp73 is able to integrate death
stimuli from three different pathways: cellular and viral on-
cogenes, some forms of DNA damage, and T cell receptor
hyperactivation. We and others have shown that deregula-
tion of the oncogenes E2F1, cMyc, and E1A induces apop-
tosis and growth suppression in tumor cells in a p53-
independent manner by transcriptionally inducing and
activating endogenous TAp73 proteins (4–7). Moreover,
during E2F1-mediated apoptosis in primary mouse embryo
fibroblasts (MEFs),
 
*
 
 a supra-additive cooperation exists be-
tween wild-type p53 and TAp73 (5). Although wild-type
MEFs show 77% apoptosis after forced E2F1 expression,
p53
 
 
 
/
 
  
 
MEFs (containing TAp73) and p73
 
 
 
/
 
  
 
MEFs (con-
taining p53) alone show reduced killing ability of only 12
and 15%, respectively. The excessively weakened killing
ability of p73
 
 
 
/
 
  
 
MEFs, despite the presence of wild-type
p53, is consistent with an important synergistic signal ema-
nating from TAp73 that cooperates with p53 to induce on-
cogene-triggered death. Because oncogene deregulation of
E2F1 is one of the most common genetic alterations in hu-
man tumors, this finding provides a possible physiologic
cause for TAp73 overexpression in tumors. Furthermore,
 
Address correspondence to Ute M. Moll, Department of Pathology, BST
L9 R134, Stony Brook University, Stony Brook, NY 11794. Phone:
631-444-2459; Fax: 631-444-3424; E-mail: umoll@notes.cc.sunysb.edu
 
*
 
Abbreviations used in this paper: 
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TAp73 is activated to mediate apoptosis by a restricted
spectrum of DNA damage. Endogenous TAp73 is activated
in response to cisplatin, and 
 
 
 
-IR in a pathway that de-
pends on the nonreceptor tyrosine kinase c-abl (8–10).
Moreover, doxorubicin stabilizes TAp73 protein by acety-
lation (11). Conversely, cells deficient in c-abl do not up-
regulate their p73 and are resistant to killing by cisplatin.
On the other hand, TAp73 is not activated by UV, actino-
mycin D, and mitomycin C, all of which activate p53 (1,
8). Lastly, peripheral T cells undergo apoptosis after hyper-
stimulation of their T cell receptors. This cell fate is medi-
ated via the E2F1–TAp73 pathway (6). Consistent with
this notion, E2F1 null mice exhibit a marked disruption of
lymphatic homeostasis with increased T cells and spleno-
megaly (12, 13). Thus, TAp73 might function indepen-
dently but synergistically with p53 in a tumor surveillance
pathway in vivo.
However, despite this strong functional homology, data
from human tumors and p73-deficient mice argue against a
classical Knudson-type tumor suppressor role for the TP73
gene. TP73-deficient mice lack a spontaneous tumor phe-
notype (14) and inactivating mutations in human tumors
are extremely rare (
 
 
 
900 tumors analyzed to date; for re-
view see reference 15). Moreover, although all normal hu-
man tissues studied express very low levels of p73, multiple
primary tumor types and tumor cell lines overexpress wild-
type p73, including cancers of the breast, lung, esophagus,
stomach, colon, bladder, ovary, liver, bile ducts, ependymal
lining, myelogenous leukemia, and neuroblastoma (15). It
is important to point out that to date, most studies identify-
ing p73 overexpression in primary human tumors have ex-
amined total levels of p73, with only a few exceptions that
specifically measured TAp73 (16, 17). Importantly, in the
mouse, an N terminally truncated 
 
 
 
Np73 protein has re-
cently been found, generated from an alternative promoter
in intron 3 and lacking a transactivation domain (18).
 
 
 
Np73 is the predominant form in the developing mouse
brain and is the only form of p73 in the neonatal brain and
sympathetic ganglia (14, 18). Mouse 
 
 
 
Np73 plays an essen-
tial antiapoptotic role during developmental p53-driven
neuronal death in vivo by acting as a dominant-negative
inhibitor of p53 (18). Functional studies have shown that
 
 
 
Np73 is required to counteract p53-mediated neuronal
death during normal “sculpting” of the developing mouse
neuronal system (18). In primary neuronal cultures, with-
drawal of the obligate survival factor nerve growth factor
leads to p53 induction with p53-dependent cell death but a
concomitant decrease of 
 
 
 
Np73. Importantly, sympathetic
neurons are rescued from cell death after nerve growth fac-
tor withdrawal or recombinant adenoviral p53 infection
when 
 
 
 
Np73 levels are maintained by viral delivery (18).
Given the existence of this powerful transdominant p53 in-
hibitor in the mouse, the possibility arose that this isoform
might in part be responsible for the overexpression seen in
human tumors and, in fact, be the crucial component.
Therefore, we sought the human counterpart of 
 
 
 
Np73,
determined whether human tumors express it and deter-
mined its potential role in cancer.
 
Materials and Methods
 
Tumor Samples and Cell Lines.
 
Primary tumors and normal
tissues were collected at University Hospital State University of
New York, Stony Brook in compliance with and approved by
the Institutional Review Board. Freshly harvested tumors (mini-
mum 60% tumor cells) and normal tissues were immediately snap
frozen in liquid nitrogen and stored at 
 
 
 
80
 
 
 
C until RNA extrac-
tion. The human breast cancer cell line MDA 231, the p53 null
lines H1299 and SaOs2, and the wild-type p53 lines U2OS,
RKO, and HeLa cells were maintained in DMEM/10% fetal calf
serum.
 
Semiquantitative RT-PCR Assay.
 
Total RNA was extracted
from tissues as previously described (17). 1 
 
 
 
g total RNA, 10
pmoles each of a radiolabeled isoform-specific upstream primer,
and a common TP73 exon 4 reverse primer were used in a 10-
 
 
 
l
reaction (Titan Kit; Roche) for 25 cycles to ensure linearity of
the assay (unpublished data) and subjected to phosphoimage anal-
ysis. Primer sequences were 5
 
 
 
-TGC TGT ACG TCG GTG
ACC-3
 
  
 
(sense 
 
 
 
Np73), 5
 
 
 
-CGA CGG CTG CAG AGC GAG-
3
 
  
 
(sense TAp73), and 5
 
 
 
-TCG AAG GTG GAG CTG GGT
TG-3
 
  
 
(antisense for both). 
 
 
 
Np73 and TAp73 amplicon sizes
were 175 and 365 bp, respectively. For Ex2Del p73, primers
were 5
 
 
 
-GCG CCA GGC CAG CCG GGA CGG AC-3
 
 
 
(sense) and 5
 
 
 
-CGC GGC TGC TCA TCT GGT CCA TGG
TGC-3
 
  
 
(antisense), which yielded a 320-bp band. Band intensi-
ties were normalized to their respective glyceraldehyde3-phos-
phate dehydrogenase (GAPDH) values. In matched samples, the
up-regulation in tumors was calculated by dividing normalized
 
 
 
Np73
 
Tumor 
 
by 
 
 
 
Np73
 
Normal
 
, TAp73
 
Tumor 
 
by TAp73
 
Normal
 
, or
Ex2Del p73
 
Tumor 
 
by Ex2Del p73
 
Normal
 
. To calculate the preferen-
tial up-regulation of 
 
 
 
Np73 in tumors, the formula 
 
 
 
Np73
 
Tumor
 
/
 
 
 
Np73
 
Normal 
 
divided by TAp73
 
Tumor
 
/TAp73
 
Normal 
 
was used. The
analogous formula was used for Ex2Del p73. Some samples were
independently repeated and yielded highly reproducible results.
Genomic sequencing of p53 exons 5–9 was performed with the
Amplimer Panel (CLONTECH Laboratories, Inc.). Immunocy-
tochemical staining for p53 was done on fixed tissue sections
from the same tumor mass.
 
Luciferase Assays.
 
A pcDNA3-based expression plasmid for
 
 
 
Np73
 
  
 
was generated with an NH
 
2
 
-terminal Flag tag.
pcDNA3-Fp53 expressing human Flag-tagged wild-type p53,
pcDNA3-p73
 
  
 
and pcDNA3-p73
 
 
 
 expressing hemagglutinin-
tagged human TAp73
 
  
 
and TAp73
 
  
 
(provided by G. Melino,
University of Rome, Rome, Italy), murine stem cell virus ex-
pressing a tetramerization domain mutant of 
 
 
 
Np73
 
  
 
called
 
 
 
Np73L322P (corresponding to L371P in TAp73
 
 
 
), and the
p53/p73-specific reporter PG13-Luc were previously described
(4). PG13 is a reporter plasmid containing 13 tandem repeats of
the p53 consensus DNA binding site. H1299 and SaOs2 cells
were transfected by Fugene (Roche). Luciferase activity was nor-
malized for renilla luciferase activity (Promega).
 
Western Blot and Coimmunoprecipitation Analysis.
 
Hela and
H1299 cells were transfected with expression plasmids for wild-
type p53 (0.5 
 
 
 
g) or TAp73
 
  
 
(0.5 
 
 
 
g) with either 1.5 
 
 
 
g
 
 
 
Np73
 
  
 
or empty vector (see Fig. 3 C). The indicated molar ra-
tios were used and green fluorescent protein (GFP) was cotrans-
fected in all cases (see Fig. 3 B). Total cell lysates were prepared
24 h later and subjected to immunoblot analysis. Gel loading was
normalized for equal vimentin or GFP levels (20 
 
 
 
g per lane).
Antibodies to p73 were monoclonal ER15 (recognizes amino ac-
ids 380–495 of human p73
 
  
 
isoforms and detects TA and 
 
 
 
N
forms; Oncogene Research Products), polyclonal anti-p73 (raised
against the COOH-terminal; Chemicon), and the polyclonal 
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anti-
 
 
 
Np73 (raised in rabbit against the exon 3
 
  
 
peptide LY-
VGDPARHLATA and immunopurified, and does not cross react
with p53 or any TAp73 isoform). Antibodies against p53 (DO-1
and PAb 421), HDM2 (IF2), p21Waf1, and 14-3-3
 
  
 
were from
Oncogene Research Products and Flag antibody (M2) was from
Sigma-Aldrich. For the normalization of protein loading, blots
were reprobed with 
 
 
 
-vimentin (BioGenex) or GFP (CLON-
TECH Laboratories, Inc., see Fig. 3 B). For coimmunoprecipita-
tions (see Fig. 5, A–C), SaOs2 and U2OS cells were transfected
with 2.4 
 
 
 
g of the indicated plasmids in single transfections, or
0.6 
 
 
 
g p53 plasmid plus 1.8 
 
 
 
g 
 
 
 
Np73
 
  
 
in cotransfections. 24 h
later, 600 
 
 
 
g lysates were subjected to immunoprecipitation with
1 
 
 
 
g of the indicated antibodies and analyzed by Western blot as
previously described (19).
For the immunoprecipitation of 
 
 
 
Np73 from tumors and nor-
mal tissues (see Fig. 2 D), frozen tissue was mechanically pulver-
ized under liquid N2, resuspended in 1.5 ml TENN buffer (50
mM Tris, 5 mM EDTA, 150 mM NaCl, 0.5% NP-40, pH 8.0)
containing a protease inhibitor cocktail (Roche), and homoge-
nized using an electric homogenizer followed by sonication for 2
min. The lysates were centrifuged twice at 14,000 rpm for 15
min. 2 mg total protein in 500 
 
 
 
l TENN was precleared four
times using 70 
 
 
 
l each time of a 1:1 mixture of protein A and G
slurry (GIBCO BRL). The last supernatant was incubated with 1
 
 
 
g ER15 antibody for 30 min at 4
 
 
 
C, followed by the addition of
40 
 
 
 
l slurry of Prot G beads. The mixture was then rotated over-
night at 4
 
 
 
C. For controls, lysates were immunoprecipitated with
monoclonal GC15 specific for p73
 
  
 
(Oncogene Research Prod-
ucts) or Flag antibody (M2). Pelleted beads were washed four
times in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Triton
X-100, 0.1% SDS, 1% NaDeoxycholate, pH 7.4), boiled in sam-
ple buffer for 3 min, and loaded onto an SDS-PAGE gel. Mem-
branes were immunoblotted with polyclonal anti-
 
 
 
Np73 (1:20)
and bands were verified by reblotting with ER15 (1:200). For
coimmunoprecipitation of a 
 
 
 
Np73–p53 complex from tissues
(see Fig. 5 D), 2 mg total protein in 500 
 
 
 
l TENN was pre-
cleared as described above and incubated with a 1:1 mixture (40
 l slurry) of agarose beads covalently coupled to the monoclonal
p53 antibodies 1801 or DO-1 (Santa Cruz Biotechnology, Inc.).
For controls, 40  l Prot G agarose slurry was used. Membranes
were immunoblotted with polyclonal anti- Np73 and bands
were verified by reblotting with ER15.
Apoptosis Assay. Hela and SaOs2 cells were seeded into
8-well chamber slides and cotransfected with 300 ng of the indi-
cated pcDNA3-based expression plasmids per well using Fugene
(see Fig. 4 A). Control wells (vector alone) received 600 ng. After
16 or 24 h, cells were stained with Annexin V or Tdt-mediated
dUTP-X nick-end labeling (TUNEL), respectively, according to
the manufacturer’s instructions (Roche). Expression was deter-
mined by immunofluorescence in duplicate wells. Transfection
efficiency was reproducibly  30% of cells, similar among all con-
structs and evenly distributed throughout the wells. Annexin V or
TUNEL positive cells (494 fields at 40 ) and plasmid-expressing
cells (15 random fields,  500 cells) were counted and the per-
centage of apoptosis in transfected cells was determined after cor-
rection for background with vector alone.
RKO cells were seeded into 8-well slides and transfected with
either vector, the irrelevant control plasmid cRel, or with
 Np73  using Lipofectamine Plus (GIBCO BRL; see Fig. 4 D).
LcRel is a transcriptionally and apoptotically inactive Flag-tagged,
truncated version of the transcription factor cRel, fused to a mi-
tochondrial targeting sequence (19) and cloned into pcDNA3. 5
h after transfection, cells were either stressed with 5  M camp-
tothecin or left untreated overnight before fixation with parafor-
maldehyde. Wells were processed for TUNEL staining followed
by immunofluorescence staining with polyclonal anti- Np73 (1:
20) and donkey anti–rabbit IgG (H L)-rhodamine conjugate
(Jackson ImmunoResearch Laboratories). Apoptosis was quanti-
tated as the percentage of  Np73 -expressing cells and compared
with vector-transfected cells.
Colony Suppression Assay. SaOs2 cells in 60-mm plates were
transfected by Fugene with 1.5  g each of the indicated expres-
sion plasmids. Vector-only plates received 3  g plasmid. 24 h
later, cells were transferred to 100-mm dishes and placed under
G418 selection (500  g/ml) for 21 d, fixed, stained with crystal
violet (20), and photographed. All foci were counted.
Mobility Shift Assays (EMSAs). H1299 and U2OS cells were
transfected with plasmids encoding wild-type p53,  Np73 , or a
combination of the two. 24 h later, nuclear extracts were prepared
by Dounce homogenization as previously described (21). As
probes, we used double stranded oligonucleotides of the p53 con-
sensus DNA binding sequences: 5 -GGGCATGTCCGGGCAT-
GTCC-3  (called p53CON) or 5 -CCTGCCTGGACTTGCC-
TGGCCTGCCTGGACTTGCCTGG-3 . EMSA was performed
with 1 ng 32 P–labeled probe and 10  g nuclear extract in bind-
ing buffer (40 mM NaCl, 10 mM morpholino propane sulfonic
acid, pH 7.0, 0.1% NP-40, 1 mM EDTA, 2.5% glycerol, 0.5  g
poly[dI-dC]) for 30 min at room temperature. Samples were
loaded onto a native 6% polyacrylamide gel and electrophoresed at
4 C and 200 V for 4 h. Where indicated, 0.5  g p53-specific
monoclonal antibody PAb 421 was included to produce a su-
pershift. Specific competition experiments included unlabeled
p53CON in 50-fold molar excess of radiolabeled probe. Nonspe-
cific competition consisted of 50-fold molar excess of the scram-
bled p53CON 5 -GGGAATTTCCGGGAATTTCC-3   or the
mutant sequence CCTTAATGGACTTTAATGGCCTTAAT-
GGACTTTAATGG (mutated nucleotides are underlined).
Antisense Suppression of  Np73. Wild-type p53-harboring
RKO cells were seeded into 8-well slides and transfected with
360 ng wild-type p53 expression plasmid with 200 nM of either
 Np73 antisense oligonucleotide directed against exon 3  with
extension into the adjacent 5  untranslated region (UTR) (anti-
sense, 5 -A*C*C*G*ACGTACAGC*A*T*G*G-3 ; stars indicate
the phosphorothioate-modified bases), or  Np73 sense oli-
gonucleotide (sense, 5 -C*C*A*T*GCTGTACGT*C*G*G*T-3 ;
both HPLC-purified, Operon Inc.) using Lipofectamine Plus or
Oligofectamine (GIBCO BRL) according to the manufacturer’s
instructions. Vector alone was also used. 20 h after transfection,
cells were subjected to immunoblotting or TUNEL staining.
Apoptosis was quantitated using a Nikon E800 microscope
equipped with a Bio-Rad confocal laser scanning system. For
each sample, the total fluorescence of five random fields per du-
plicate well was acquired with a 20  lens using identical acquisi-
tion and photomultiplier settings. Data were processed to calcu-
late the integral optical density using the Laser Pix software
package (Bio-Rad Laboratories). In other experiments, RKO
cells were transfected with 200 nM each of the antisense and sense
oligonucleotides listed above. After 8 h, cells were DNA damaged
by adding 1  M camptothecin for an additional 16 h before
TUNEL staining. Apoptosis was determined as described above.
Results
The Human TP73 Gene Can Produce  Np73. Mouse
 Np73 differs from TAp73 by a novel exon 3 , which re-768  Np73 Is Up-regulated in Human Tumors
places the first 3 exons and is spliced in frame to exon 4 of
the TP73 gene (18). To clone the human homologue of
mouse   Np73, we performed a GenBank search using
mouse exon 3 . By sequence alignment of a human ge-
nomic P1 artificial chromosome clone containing TP73
(sequence data are available from GenBank/EMBL/DDBJ
under accession no. AL 136528), we identified a region
with 77% identity to the 5   UTR of mouse  Np73
mRNA (sequence data are available from GenBank/
EMBL/DDBJ under accession no. Y 19235). This allowed
us to predict the human exon 3  and design isoform-spe-
cific primers for human  Np73. Full-length  Np73 
cDNA, spanning exons 3 –14 including 103 bases of 3 
UTR, was cloned by RT-PCR from total RNA of human
placenta and MDA 231 breast cancer cells, and sequence
was confirmed (Fig. 1 A). To confirm that  Np73 derives
from a separate promoter upstream of exon 3 , we per-
formed 5   rapid amplification of cDNA ends and se-
quenced the 5  UTR upstream of exon 3  (Fig. 1 C). Hu-
man exon 3  encodes 13 unique amino acids with almost
complete identity to mouse exon 3  (12 out of 13 residues
are identical; Fig. 1 A). The human  N promoter contains
the predicted TATA box 25 nucleotides upstream of the
transcriptional start site, which is located 7.6 kb down-
stream of exon 3.
Expression of  Np73 and Ex2Del p73 in Human Tu-
mors. Unique cDNA primers were designed for amplifi-
cation of  Np73 from tissues by semiquantitative RT-
PCR (Fig. 1 B). Then, we determined if expression levels
of   Np73 were tumor specifically up-regulated using a
spectrum of human tumor pairs that were matched with
the patients’ normal tissues of origin (Table I and Fig. 2 A).
They included 35 cancers (cancers of the ovary, en-
dometrium, cervix, vulva, vagina, breast, kidney, and co-
lon) and 2 large benign ovarian tumors (serous cystade-
noma and serous cystadenofibroma). Indeed, in 27 of the
37 pairs (73%),  Np73 was specifically up-regulated be-
tween 2- and 150-fold in the patients’ tumors compared
with their matched normal tissues (Table I, second col-
umn). In a subset of our matched pairs, we also determined
the expression of the previously described Ex2Del p73
(23). Ex2Del p73 is another isoform of p73 that lacks most
of the transactivation domain, but in contrast to  Np73 it
is generated from the same promoter as TAp73 by splicing
out exon 2. Ex2Del p73 was shown to be up-regulated in
some ovarian and vulval cancers and breast cancer cell lines
and is a transdominant inhibitor of p53 (22–24). As already
seen with  Np73, Ex2Del p73 was also specifically up-
regulated 2.2–20-fold in 11 of 22 analyzed tumors (50%)
compared with their matched normal tissues either alone
or concomitant with  Np73 (Table I, third column, and
Fig. 2 A). Taken together, 30 of 37 tumor pairs (81%) ex-
hibited tumor-specific up-regulation of  Np73 and/or
Ex2Del p73. On the other hand, because we previously
showed that breast cancers can overexpress TAp73 (17),
we next used isoform-specific RT-PCR to simultaneously
measure  Np73 and TAp73. TAp73 was up-regulated in
18 of 37 tumors (49%; Table I, fourth column) compared
Figure 1. Gene architecture of human TP73. (A) In contrast to TP53,
which harbors a single promoter generating a single protein composed of
the transactivation domain (TAD), DNA-binding domain (DBD), and
tetramerization domain (TD), the TP73 gene is complex and contains
two promoters and an additional sterile   motif domain (SAM). The P1
promoter in the 5  UTR region produces transactivation-competent full-
length proteins containing the TA domain (TAp73). The P2 promoter in
intron 3 produces TA-deficient protein(s) ( Np73) with dominant-neg-
ative function toward TAp73 and wild-type p53.  Np73 starts with
exon 3 , which encodes 13 unique amino acids that are highly conserved
between human and mouse. Another NH2 terminally truncated p73,
Ex2Del, also lacks the TA domain but is created by splicing out exon 2
from the P1 transcript (reference 1). The COOH-terminal of TAp73 un-
dergoes additional exon splicing, which generates  -  isoforms. (B) Po-
sitions of the P1 and P2 promoters. Positions of the RT-PCR primers
are indicated: TAp73 (bottom),  Np73 (center), and Ex2Delp73 (top).
(C) Sequence of the 5  UTR region of  Np73. The putative TATA box
is indicated.769 Zaika et al.
Table I. Expression of  Np73, ExDel p73, and TAp73 in Matched Human Tumors
No. Tumor
Increased  Np73
expression in
tumor vs. normal
Increased Ex2Del
expression in
tumor vs. normal
Increased TAp73
expression in
tumor vs. normal
Preferential up-regulation
of  Np73 or Ex2Del
vs. TAp73 in tumors p53 status
1 Endometrial Ca 150 5 6.5 23 — wt, sequence confirmed
2 Endometrial Ca 100 — 7 14.2 — mut
3 Cervical Caa 78 nd 7 11 nd wt
4 Vaginal Ca 38 — — 2,794 — mut
5 Ovarian Ca 36 nd 3 12 nd wt, sequence confirmed
6 Cervical Ca 25 nd 155 — nd mut Ex 8, R273H
CGT→CAT
7 Ovarian Ca 21 nd 4 5 nd wt, sequence confirmed
8 Ser cystadenofibr 20 — — 21 — wt
9 Ovarian Ca 13 6.1 10.5 1.2 — mut
10 Ovarian Ca 12 — — 26.6 — wt
11 Breast Ca 12 nd — 11 nd wt, sequence confirmed
12 Endometrial Ca 11 2.5 10 1.1 — wt
13 Breast Caa 10 nd — 16 nd wt, sequence confirmed
14 Endometrial Ca 8 3 32 — — wt
15 Vulvar Ca 7.6 3.2 5.3 1.4 — mut
16 Endometrial CaSar 6 20 — 6 — mut
17 Ovarian Ca 5.5 — — yes* —w t
18 Ovarian Ca 5 — 6.6 — — mut
19 Ovarian Ca 4.6 4 42 — — mut
20 Ovarian Ca 4 nd 10 — nd mut Ex 5, C176Y
CGC→TGC
21 Ovarian Caa yes* nd — yes* nd
mut Ex 6, R213STOP
CGA→TGA
22 Ovarian Ca yes* nd yes* yes* nd wt
23 Ser cystadenoma 3 nd — 8 nd wt
24 Ovarian Ca 2.6 — 13 — — mut
25 Vulvar Ca 2.5 2.2 3.7 — — wt
26 Bord Muc Ov Tu 2.4 — — 2.3 — wt
27 Ovarian Ca 2 — 3.3 — — mut
28 Breast Caa — nd 29 — nd wt
29 Endometrial Ca — 2.4 — — 2 wt
30 Endometrial Ca — — — — — wt
31 Ovarian Ca — — — — — wt
32 Ovarian Ca — yes* — — yes* wt
33 Ovarian Caa —n d—— n d
34 Breast Ca — nd — — nd wt
35 Ovarian Ca — nd — — nd mut
36 Renal Ca — nd — — nd
37 Colon Ca — yes* — — yes*
Numbers reflect fold increase. yes*, cannot be calculated as fold increase because level in normal tissue is undetectable; Ca, carcinoma; ICC,
immunocytochemistry for p53 with monoclonal antibody DO-1 (negative suggests wild-type status, positive suggests mutant status); nd, not
determined; Ser cystadenofibr, serous cystadenofibroma (a large benign ovarian tumor); Ser cystadenoma, serous cystadenoma (a large benign ovarian
tumor); Bord Muc Ov Tu, borderline mucinous ovarian tumor (a large ovarian tumor of low or uncertain malignant potential).
aAverage of two independent measurements. Values differed by  10%.770  Np73 Is Up-regulated in Human Tumors
with its respective normal tissues of origin. However, al-
though tumors with deregulated  Np73 and/or Ex2Del
p73 also tended to show up-regulation of TAp73, the
magnitude of the  Np73 and/or Ex2Del p73 up-regula-
tion was much higher than that of TAp73 in the majority
of cases. Among the 31 tumor pairs with up-regulation of
any one or all of these three p73 transcripts, 22 tumors
(71%) exhibited preferential up-regulation of  Np73 (19
tumors; Table I, left side of fifth column) or Ex2Del p73 (3
tumors; Table I, right side of fifth column). These included
13 ovarian cancers and 2 large benign ovarian tumors, 5
endometrial cancers, 2 breast cancers, 2 cervical cancers,
and 2 vulvar cancers. Moreover, 14 of these 22 tumors
(67%) exhibited exclusive up-regulation of  Np73 and/or
Ex2Del p73. (“preferential” up-regulation means that the
up-regulation of  Np73 and/or Ex2Del p73 was more
marked than the up-regulation of TAp73). In one case,
the tumor showed preferential  Np73 up-regulation of
Figure 2.  Np73 is frequently overexpressed in a vari-
ety of primary human cancers. (A) Tumor-specific up-reg-
ulation of  Np73 (solid bars) transcripts in 35 tumor pairs,
compared with their respective normal tissues of origin. In
addition, Ex2Del p73 transcripts (gray bars) were measured
in a subset of pairs. Ex2Del p73 is another previously de-
scribed isoform of p73 that lacks most of the transactivation
domain. In contrast to  Np73, it is generated from the
same promoter as TAp73 by splicing out exon 2. It is also a
transdominant inhibitor of p53 (references 22–24). Iso-
form-specific semiquantitative RT-PCR assay from total
RNA extracted from human tissues (see Table I). Two tu-
mor pairs (nos. 21 and 22) had readily detectable  Np73
levels in tumor tissues but failed to give detectable  Np73
levels in their corresponding normal tissues. Therefore,
fold up-regulation could not be quantitated in those 2 cases
reducing the total number plotted from 37 to 35 cases. Ex-
pression levels, standardized for their corresponding
GAPDH values, were used to calculate fold induction as
described in Materials and Methods. (B) Up-regulation of
 Np73 transcripts in a series of unmatched 52 human
breast cancers compared with 8 unrelated normal breast
tissues.   Np73-specific semiquantitative RT-PCR assay
from total RNA extracted from tissues. Expression levels
were standardized using the corresponding GAPDH value of each sample. The relative expression of  Np73 in breast cancers and normal breast tissues is
shown. The average normal tissue expression (gray line) is indicated. The arrow marks an arbitrary cut-off, delineating tumors with fivefold or higher
 Np73 overexpression. 16 of 52 breast cancers (31%) overexpress  Np73 levels that were between 6- and 44-fold higher than that of average normal
breast tissue. (C) Characterization of the polyclonal anti- Np73. Anti- Np73 does not recognize TAp73 , TAp73 , or p53. H1299 cells were trans-
fected with empty vector or the indicated expression plasmids and lysates (50  g protein for lanes 1–5 and 10  g for lanes 6–9) were immunoblotted
with either a cocktail of ER15, GC15, and DO-1 (lanes 6–9) or anti- Np73 (lanes 1–5). (D) Tumor-specific up-regulation of  Np73  protein. Cases 9,
14, and 26 (top from left to right) and cases 10, 31, and 1 (bottom) from Table I are shown. Immunoprecipitations of equal amounts of total protein (2
mg each) from matched pairs of homogenized tumor/normal tissues with 1  g anti-p73 antibody ER15 followed by immunoblotting with polyclonal
anti- Np73. Hc, heavy chain. The last lane (top) is a positive control of H1299 lysate transfected with a  Np73  expression vector.771 Zaika et al.
 2,700-fold compared with TAp73 expression (tumor no.
4). Only nine tumors (29%) exhibited an inverse ratio with
a disproportional rise of TAp73 compared with their rise
in   Np73. Thus, taken together, in our series of 31
matched tumors with some form of tumor-specific deregu-
lation of the TP73 gene, 22 tumors (71%) exhibit either
exclusive or preferential up-regulation of dominant-nega-
tive p73 isoforms.
In our paired tumor series, we had an overall p53 muta-
tional rate of 38%, as determined either by direct sequenc-
ing of the PCR-amplified DNA binding domain or by im-
munocytochemically shown nuclear overexpression (Table
I). This prevalence is in agreement with the reported rates
of p53 mutations in these tumor types ( 40%; reference
25). We reasoned that if  Np73 and Ex2Del p73 were in-
deed p53- and TAp73-directed inhibitors and would act as
oncogenes, one would expect to see their expression pref-
erentially in wild-type p53 tumors. Of the 22 tumors with
preferential up-regulation of  Np73 and/or Ex2Del p73,
21 tumors were available for p53 mutational analysis. Of
these 21 tumors, 15 tumors harbored wild-type p53 (71%).
In contrast, among the nine cases with preferential up-reg-
ulation of TAp73, six tumors harbored mutant p53 (66%).
We then analyzed this set of 30 tumors for a correlation be-
tween overexpression of dominant-negative forms of p73
and concomitant wild-type p53 status. When all tumors
were included, a statistical trend but no significance was
found by Student’s t test. When the unusual tumor number
4 is excluded, which is characterized by a singularly high
level of  Np73 up-regulation of almost 3,000-fold com-
pared with TAp73 up-regulation plus a mutant p53 status,
statistical significance was found (P   0.014). Taken to-
gether, a correlation between tumor-specific up-regulation
of  Np73 or Ex2Del p73 and wild-type p53 status of the
tumor cannot be made with this limited set of tumors, al-
though a trend is present. More tumor samples will need to
be analyzed in the future to support the hypothesis that the
expression of dominant-negative p73 isoforms alleviates the
selection pressure for p53 mutations in tumors.
To further investigate whether tumors up-regulate
 Np73, we determined  Np73 transcript levels in a series
of 52 unmatched breast cancers and compared them to 8
available normal breast tissues from unrelated individuals
(Fig. 2 B). 16 of 52 breast cancers (31%) overexpressed
 Np73 levels that were between 6- and 44-fold higher
than the average of the 8 normal breast tissues (Fig. 2 B,
gray line). An additional 10 tumors showed  Np73 up-
regulation between two- and sixfold above the normal av-
erage. In contrast, four normal breast tissues showed non-
detectable levels of  Np73, two cases expressed at average
level, and only two tissues were elevated two- to fourfold.
Next, we used isoform-specific semiquantitative RT-
PCR to simultaneously measure  Np73 and TAp73 be-
cause we previously showed that breast cancers can also
overexpress TAp73 (17). Among the 16 cancers with a
6–44-fold increase of  Np73, 12 cancers again showed
preferential up-regulation of  Np73 over TAp73 (unpub-
lished data). Although the data is not complete enough to
make strong conclusions, as we had already seen in the gy-
necological cancers on Table I, our results on breast can-
cer again suggests that  Np73 might selectively be up-
regulated during tumorigenesis.
To confirm that tumor-specific up-regulation of  Np73
transcripts translate to the up-regulation of proteins, we
generated a  Np73-specific polyclonal antibody raised
against the unique exon 3 . This antibody recognizes
 Np73 but does not cross react with TAp73 , TAp73 ,
or p53 (Fig. 2 C). Using this reagent, we determined
 Np73 protein expression on 10 matched pairs of homog-
enized tumor/normal tissues from Table I. Tissues were
subjected to immunoprecipitations of equal amounts of to-
tal protein (2 mg each) with the anti-p73 specific antibody
ER15 followed by immunoblotting with polyclonal anti-
 Np73. Some examples are shown in Fig. 2 D, which rep-
resent cases 1, 9, 10, 14, 26, and 31. Tumor-specific up-
regulation of  Np73 protein was found in all 10 cases as
demonstrated by tumors yielding detectable  Np73 
protein, whereas their respective matched normal tissue
showed a complete absence of  Np73  protein in nine
cases and only a minute amount in case number 10. More-
over, when tumor lysates in these cases (2 mg each)
were immunoprecipitated with nonspecific Flag antibody,
 Np73 protein could not be detected (unpublished data).
Also, the immunoprecipitation of cases 9, 14, and 26 with
 -specific anti-p73 antibody GC15 did not yield  Np73
protein, indicating that in contrast to  Np73 ,  Np73  is
not up-regulated to detectable levels in these cases. As ex-
pected, no strict correlation between the levels of tumor-
associated protein and the ranking in Table I is present be-
cause the RT-PCR measurements indicate the relative fold
increase of mRNA levels of tumor versus normal rather
than absolute values. Interestingly, cases 26 and 31 did not
exhibit increased  Np73 expression of their tumors at the
transcript level, yet clearly do so on the protein level. This
notion warrants additional investigation because it might
suggest that the prevalence of tumor-associated  Np73 up-
regulation is somewhat higher than transcript measure-
ments would predict.
 Np73 Is an Efficient Dominant-Negative Inhibitor of the
Transcription Function of Wild-type p53 and TAp73. To test
the hypothesis that human  Np73 is a dominant-negative
inhibitor of human wild-type p53 and TAp73, we first per-
formed reporter assays with expression plasmids for wild-
type p53, TAp73 , TAp73 , and a p53/TAp73-responsive
luciferase reporter in the presence or absence of  Np73 
using p53 null H1299 and SaOs2 cells (Fig. 3, A–C, and
unpublished data). Increasing ratios of  Np73  expression
plasmid were added to a constant amount of p53 or
TAp73  and TAp73  plasmids. Fig. 3 B shows that the
p53 expression levels in this assay were independent of the
amount of  Np73  added, and that p53 and TAp73 ex-
pression levels were not interfering with the amount
of  Np73  expressed. Surprisingly, the steady state levels
of TAp73   actually increased in proportion to the
amount of  Np73  added, despite the fact that the same
amount of TAp73  plasmid was used in all reactions. Of772  Np73 Is Up-regulated in Human Tumors
note, the addition of  Np73  exhibited complete suppres-
sion of the transcriptional activity of wild-type p53, TAp73 ,
and TAp73  in a dose-dependent manner (Fig. 3 A and un-
published data). Furthermore,  Np73  also efficiently sup-
presses endogenous target gene products of wild-type p53
and TAp73 (Fig. 3 C and unpublished data). In HeLa and
H1299 cells, the transfection of wild-type p53 or TAp73  in-
duces endogenous HDM2, 14-3-3 , and p21Waf1 com-
pared with basal levels seen with empty vector. However, the
concomitant expression of  Np73  strongly suppresses each
of these response gene products (compare lanes 2 and 3 and
lanes 4 and 5). Expression of  Np73  alone did not suppress
these target genes (compare lanes 6 and 7).
 Np73 Is an Efficient Dominant-Negative Inhibitor of the
Apoptosis and Suppressor Function of Wild-type p53 and
TAp73. Moreover,   Np73   is a strong inhibitor of
apoptosis induced by wild-type p53 and TAp73 (Fig. 4 A).
HeLa and SaOs2 cells undergo wild-type p53- and TAp73-
dependent cell death as assessed by Annexin V staining and
TUNEL assay. This apoptotic activity is completely abol-
ished by the coexpression of  Np73  (Fig. 4 A and
unpublished data). The inhibitory action of  Np73  is de-
pendent on the presence of transcription-competent wild-
type p53 and TAp73 because  Np73  alone cannot affect
apoptosis (Fig. 4 A, left column). Furthermore, in agree-
ment with the antiapoptotic effect,  Np73  is an inhibitor
of colony suppression mediated by wild-type p53 and
TAp73 (Fig. 4 B and Table II). The reintroduction of
wild-type p53 and TAp73 suppresses the growth of SaOs2
cells (2, 26) and this suppression is thought to be largely
due to apoptosis (27). In keeping with these results, the
transfection of wild-type p53 strongly suppresses macro-
scopic colony formation of SaOs2 cells compared with
many visible colonies with vector backbone alone (4 foci
for wild-type p53 vs. 1,778 for vector control; Fig. 4 B and
Table II). As expected, the expression of  Np73  alone
has no growth-promoting effect compared with vector
controls (1,383 vs. 1,778 foci), but was actually slightly
Figure 3.  Np73 is an efficient dominant-negative in-
hibitor of the transcriptional activity of wild-type p53 and
TAp73. (A)  Np73 -mediated suppression of the wild-
type p53/TAp73-responsive reporter construct PG13-
luciferase in p53 null H1299 cells. Luciferase activity is
normalized for renilla luciferase activity. Coexpressed
 Np73  causes a dose-dependent complete suppression of
the transcriptional activity of wild-type p53 and TAp73 .
Suppression by  Np73  for the molar ratios of wild-type
p53 or TAp73  to  Np73  are indicated. Results are the
average   SD of three independent experiments. Results
were similar with TAp73  (unpublished data). (B) Immuno-
blots of H1299 cells transfected with p53 or TAp73  alone or
with increasing amounts of  Np73 . GFP was cotransfected
in all cases. Transfections were done in parallel with A.
Lane loading was normalized for GFP levels. (C)  Np73 
suppresses the wild-type p53 and TAp73 -induced trans-
activation of endogenous target genes. p53 null H1299 cells
were transfected with expression plasmids containing wild-
type p53 or TAp73  with either empty vector or  Np73 
at a 1:3 molar ratio. Lane 7 was transfected with empty
vector plus  Np73  at a 1:3 molar ratio. Transfected crude
lysates, normalized for equal protein loading by vimentin,
were immunoblotted for HDM2, 14-3-3 , and p21Waf1.
Cells in the Vect lane are transfected with pcDNA3 only.773 Zaika et al.
growth suppressive in these p53 null cells for reasons that
are unclear. In contrast, the coexpression of  Np73  with
wild-type p53 at a 1:1 molar ratio counteracts this effect,
leading to a 12.5-fold increase in the number of colonies
from 4 to 51 foci. Likewise, TAp73 , although not quite as
potent as wild-type p53, suppresses colony formation (82
Figure 4.  Np73  counteracts apoptosis and sup-
pression of tumor cell growth induced by wild-type
p53 and TAp73. (A) Annexin V analysis of apoptosis.
HeLa cells were transfected with expression plasmids
encoding wild-type p53 or TAp73  with either empty
vector or  Np73  at a 1:1 molar ratio and analyzed af-
ter 16 h. As control,  Np73  plus empty vector was
used. For each construct, the number of expressing cells
was determined by immunofluorescence and the apop-
totic index of expressing cells is indicated. Results are
the average   SD of four independent experiments.
Similar results were obtained with SaOs2 cells and with
TUNEL analysis. (B) SaOs2 colony suppression in-
duced by wild-type p53 and TAp73  is inhibited by  Np73 . Number of colonies are shown in Table II. (C) p53 expression analysis of random SaOs2
clones derived from surviving colonies of a parallel experiment to the one shown in B. Immunoblots with anti-p53 antibody DO-1 using 30  g total cell
lysate per lane. Clones from cells originally transfected with expression plasmids for wild-type p53 alone (left) or wild-type p53 plus  Np73  (right). Ex-
cept for clone 6, all other wild-type p53-transfected clones have lost full-length p53 protein expression. Clones 1, 3, and 5 show no detectable p53 protein
at all, whereas clones 2, 4, and 6 express truncated p53 polypeptides (left). In contrast, all six colonies derived from cotransfection with wild-type p53 and
 Np73  show detectable levels of full-length p53 protein with sequence-confirmed wild-type status of the DNA binding domain in three of three tested
clones (right, five clones are shown). Immunoblot to show  Np73  expression in SaOs2 clones 8–12 compared with a SaOs2 clone transfected with
empty vector (bottom). (D)  Np73  confers drug resistance to wild-type p53/TAp73 harboring tumor cells. RKO cells were transfected with empty
vector (left), the irrelevant expression plasmid LcRel (center), or with  Np73  expression plasmid (right). 5 h after transfection, cells were treated with 5
 M camptothecin overnight or left untreated (not depicted). After fixation with paraformaldehyde, each well underwent both TUNEL staining in green
and immunofluorescence with  Np73-specific polyclonal antibody (left and right) or Flag antibody (center) in red to assess apoptosis and expression. In
contrast to vector-only or LcRel-transfected cells,  Np73 -expressing cells (right white arrows) are virtually protected from camptothecin-induced apop-
tosis. The p73 antibody produces a slight background staining in empty vector–transfected RKO cells, which allows the counting of all cells in the well
(left). The percentage of apoptosis of  Np73 -expressing and control-transfected cells after 24 h of treatment with 5  M camptothecin is shown.774  Np73 Is Up-regulated in Human Tumors
foci), but the coexpression of  Np73  with TAp73  again
antagonizes this effect and increases the number of macro-
scopic colonies by 8.1-fold to 669 foci. Taken together,
 Np73 is an efficient dominant-negative inhibitor of wild-
type p53 and TAp73, although the strong repressive effect
of  Np73  on p53 and TAp73 seen in transient assays (Fig.
4 A) is more modest in long-term assays (Fig. 4 B). Entirely
consistent with this finding were data from a subsequent
p53 expression analysis of SaOs2 cell clones that were es-
tablished from surviving colonies of a duplicate experi-
ment. A complete loss of full-length p53 protein expression
was found in five out of six such randomly picked clones
that were derived from plates transfected with wild-type
p53 alone (Fig. 4 C, left). Although clones 1, 3, and 5
showed no detectable p53 protein at all, clones 2, 4, and 6
expressed only truncated and presumably nonfunctional
p53 polypeptides, likely due to chromosomal rear-
rangement. The functional significance of the very small
amounts of full-length p53 protein detectable in clone 6 is
unclear, in light of the presence of coexpressed truncated
p53. On the whole, this data is in agreement with the fact
that wild-type p53 expression is incompatible with the out-
growth of clones in this assay, and rare colonies escape be-
cause they have lost wild-type p53 expression (28). In con-
trast, all six randomly picked colonies derived from plates
cotransfected with wild-type p53 and  Np73  exhibited
only full-length p53 protein (Fig. 4 C, five clones are
shown). Upon sequencing the DNA binding domain of
three of these clones, all three revealed wild-type p53 ge-
notypes. All clones expressed elevated levels of  Np73 
protein compared with endogenous levels (Fig. 4 C).
Taken together, this data indicates that the coexpression of
 Np73  neutralizes the growth-suppressive effect of wild-
type p53, thereby removing the selection pressure for the
deletion or rearrangement of wild-type p53.  Np73  is
able to effectively counteract p53- and TAp73-induced
colony suppression in transformed human cells.
 Np73  Confers Drug Resistance to Wild-type p53-harbor-
ing Tumor Cells. Because we have shown that  Np73 is
an efficient inhibitor of exogenous wild-type p53-mediated
apoptosis and growth suppression, we next tested whether
 Np73  also inhibits endogenous wild-type p53-mediated
apoptosis after DNA damage. RKO cells, a human colon
cancer line harboring wild-type p53 and TAp73, were
transfected with empty vector, an irrelevant control plas-
mid (LcRel), or with  Np73   expression plasmid and
treated with either 5  M camptothecin or left untreated
(Fig. 4 D). Camptothecin is a topoisomerase inhibitor gen-
erating single and double strand DNA breaks, which in-
duce an increase of p53 and TAp73 protein levels (29). As
expected, control cells treated with camptothecin and
transfected with either empty vector or LcRel underwent
marked apoptosis with 44 and 39% of cells dying after 24 h.
In contrast,  Np73 -expressing camptothecin-treated cells
were strongly protected from drug-induced apoptosis,
causing only 6% of cells to die. Thus,  Np73  protects hu-
man cancer cells from p53- and TAp73-induced cell death
mediated by a chemotherapeutic agent.
 Np73 Inhibits Wild-type p53 and TAp73 Function by
Heterocomplex Formation. One explanation for the ob-
served dominant-negative effect is a direct physical interac-
tion between  Np73 and either wild-type p53 or TAp73
proteins, analogous to the dominant-negative mode of ac-
tion of mutant p53 proteins toward wild-type p53. To test
this hypothesis directly, lysates prepared from p53 null
SaOs2 cells cotransfected with wild-type p53 and  Np73 
were immunoprecipitated with monoclonal antibody
ER15, which recognizes  Np73 . Immunoblot analysis
with an antibody specific for p53 (CM1) revealed a com-
plex of the two proteins (Fig. 5 A, lane 3). Of note, TAp73
isoforms are unable to form a protein complex with wild-
type p53 (Fig. 5 A, lane 7, B, lane 3, and C, lane 1; refer-
ences 18 and 30–32), excluding the possibility that the
observed p53 band was coimmunoprecipitated via the en-
dogenous TAp73 protein of SaOs2 cells. As control, no
such complex was seen in SaOs2 cells transfected with ei-
ther empty vector, TAp73 , or  Np73  alone (Fig. 5 A,
lanes 1, 2, and 4), nor was a complex seen in SaOs2 cells
transfected with p53 alone or with p53 plus TAp73  (Fig.
5 A, lanes 6 and 7), indicating the specificity of the p53–
 Np73  complex. Moreover, a similar complex was seen
in wild-type p53-expressing human U2OS cells after trans-
fection with  Np73  alone. Fig. 5 B shows a specific com-
plex between endogenous wild-type p53 and ectopic
 Np73   that was immunoprecipitated by ER15 from
U2OS cells (lane 1). No such complex was seen when an
irrelevant monoclonal antibody against GFP was used (lane
2), or when TAp73   or empty vector were expressed
(lanes 3 and 4). The same specific complex can again be
immunoprecipitated from U2OS cells using a monoclonal
antibody specific for p53 (421) and immunoblotted with
the polyclonal antibody specific for  Np73 that does not
cross react with any TAp73 proteins (Fig. 5 C, lane 2).
Again, no such complex is found with preimmune mouse
IgG (Fig. 5 C, lane 3) or when U2Os cells were transfected
with TAp73  (lane 1) or vector (unpublished data). The
lysate lane in Fig. 5 A represents 5% of the immunoprecip-
itation input and the lysate lane in Fig. 5 C represents
2–10% of the immunoprecipitation input, depending on
the experiment. Together, this data indicates that a small
Table II. Inhibition of Colony Suppression by  Np73
Plasmid No. of foci SDa
vect 1,778 213
 Np73 1,383 194
wtp53 4 8
wtp53 plus  Np73 51 14
TAp73  82 16
TAp73  plus  Np73 669 187
wtp53, wild-type p53.
aData are derived from three independent experiments.775 Zaika et al.
but highly reproducible portion of  Np73 forms a stable,
specific complex with wild-type p53 in cells. To confirm
the existence of this complex in vivo in tumor tissues, we
coimmunoprecipitated the  Np73–p53 complex from an
ovarian carcinoma and an endometrial carcinoma with
wild-type p53 status (see example in Fig. 5 D, lane 1). Of
note, this mixed complex was only seen in the patients’ tu-
mors but not in the corresponding normal ovarian tissues
(Fig. 5 D, lane 2). Moreover, no specific complex was seen
when the immunoprecipitating anti-p53 antibody beads
were substituted by protein G beads (lanes 3 and 4).
We also examined the second possibility, namely direct
competition for specific DNA binding between  Np73 
and wild-type p53 at the promoter level. Gel shift assays
were performed with two different p53-specific DNA
binding sequences as probes, using nuclear extracts of
H1299 or U2OS cells transfected with expression plasmids
for p53 alone or in combination with  Np73 . Although
nuclear extract transfected with empty vector showed no
specific DNA complex (Fig. 6 A, lane 1), p53 formed a
specific complex (lane 2) that could be supershifted with
the p53-specific antibody PAb 421 (lane 3) and competed
off with 50-fold excess of unlabeled specific probe (lane 4).
Likewise, p53 only binds to the specific probe (Fig. 6 A,
lane 9), but not to a scrambled version of the specific probe
(lane 11). The specific p53/DNA band (Fig. 6 A, lane 9) is
supershifted by antibody 421 (lane 10), but 421 cannot
produce a “false” supershifted band when p53 fails to bind
to the scrambled probe (lane 12). Extracts from cells trans-
fected with  Np73  alone failed to bind to both probes
despite high levels of  Np73  expression on immunoblots
(Fig. 6 A, lane 8, and unpublished data). However, nuclear
extracts from cells cotransfected with p53 and  Np73  at a
1:4 ratio showed a slight decrease in p53–DNA complex
formation (Fig. 6 A, compare lanes 2 and 5), which became
more pronounced at a 1:20 ratio of p53 to  Np73  (com-
pare lanes 6 and 7). Moreover, in a p53 reporter assay using
PG13, a tetramerization-incompetent but DNA binding–
competent mutant of  Np73 , called  Np73 L322P (cor-
responding to L371P in TAp73 ; reference 4), showed a
significant but incomplete reversal of the dominant-nega-
tive inhibition of p53 transactivation by  Np73  (Fig. 6
B). These results support the notion that competition at the
promoter site is another mode of inhibition. Taken to-
gether, the formation of inactive heterooligomers between
p53 and  Np73 appear to play a role in the dominant-neg-
ative inhibition of p53 by  Np73. Such complexes occur
naturally in primary tumors and in cultured cells. On the
Figure 5. Physical interaction between
 Np73  and wild-type p53 proteins in can-
cer cell lines and human tumors. (A) Crude
cell lysates of p53 null SaOs2 cells trans-
fected with the indicated expression plas-
mids were immunoprecipitated with the
monoclonal antibody ER15 and immuno-
blotted for coprecipitating wild-type p53
with polyclonal CM-1. ER15 is a p73 anti-
body against a COOH-terminal epitope
and reacts with both  Np73  and TAp73 .
ER15 is used here to immunoprecipitate
 Np73   because complexes between
TAp73 and wild-type p53 do not occur
(lane 7 and B and C; references 18 and 30–
32). Only lysate was loaded in lane 5. The
shadow band in lanes 4, 6, and 7 is derived
from the heavy chain of added ER15. (B) Crude cell lysates of wild-type p53 harboring U2OS cells transfected with the indicated plasmids were immu-
noprecipitated with ER15 or an irrelevant monoclonal antibody against GFP and immunoblotted for coprecipitating endogenous p53 with polyclonal
CM-1. (C) Crude cell lysates of U2OS cells transfected with the indicated plasmids were immunoprecipitated with a monoclonal antibody against p53
(421) or irrelevant mouse IgG and immunoblotted for coprecipitating  Np73  with polyclonal anti- Np73. This antibody is raised and immunopurified
against exon 3  and does not cross react with TAp73 isoforms or p53. Only lysate was loaded in the indicated lane. (D) Detection of tumor-specific pro-
tein complexes between  Np73  and wild-type p53 in an ovarian carcinoma. Immunoprecipitations of equal amounts of total protein (2 mg each) from
a matched pair of homogenized tumor/normal tissues using a mixture of anti-p53 antibodies DO-1 and 1801 covalently coupled to agarose beads, followed
by immunoblotting with polyclonal anti- Np73. The  Np73 –p53 protein complex is detectable in the tumor but not in the respective normal tissue.
Equal amounts of the same tumor and normal tissue lysates immunoprecipitated with protein G–coupled beads are used as an additional negative control.
The last lane is a positive control of H1299 lysate transfected with a  Np73  expression vector.776  Np73 Is Up-regulated in Human Tumors
other hand, competition between  Np73 and p53 at the
level of the promoter, where the presence of  Np73 inter-
feres with the ability of p53 to bind effectively to its cog-
nate binding site, might be a second mechanism that is
physiologically relevant. Using nuclear extracts of  Np73-
transfected cells, however, we failed to obtain clear evi-
dence that  Np73  alone can directly bind to p53 cognate
sites. This issue justifies additional studies.
Suppression of  Np73 Enhances Apoptosis Mediated by p53
and TAp73. Our studies demonstrate a dominant-nega-
tive action of  Np73 toward the apoptosis, focus suppres-
sion, and transactivation functions of p53 and TAp73
within the context of forced  Np73 expression. To test
whether  Np73 would have the same inhibitory effect in
cells when present at endogenous levels, we used antisense
oligonucleotides to suppress endogenous  Np73 expres-
sion in wild-type p53-harboring RKO cells that undergo
apoptosis after DNA damage. RKO cells treated with
camptothecin alone underwent a certain level of apoptosis
(Fig. 7 A, left bar). In contrast, the preincubation of RKO
cells with antisense oligonucleotides directed against the
unique exon 3  of  Np73 showed a significant enhance-
ment of p53-mediated apoptosis after camptothecin stress
(Fig. 7 A, center bar), whereas camptothecin-stressed RKO
cells pretreated with the sense version of the same oligonu-
cleotide did not (Fig. 7 A, right bar). To further confirm
that the gain in apoptotic ability seen after down-regulation
of endogenous  Np73 was in fact due to specific derepres-
sion of p53-mediated apoptosis, we modified the above ex-
periment by directly transfecting p53. RKO cells were
Figure 6. Mechanism of the dominant-negative
effect of  Np73. (A) EMSA using nuclear extracts of
H1299 cells transfected with expression plasmids for
p53 or  Np73  alone or in combination. Competition
of sequence-specific binding of p53 by  Np73   is
shown (compare lanes 6 and 7).  Np73  alone does
not bind to the p53 cognate site, p53CON (lane 8).
Anti-p53 antibody (421) was added as indicated. (B)
p53 reporter assay using the p53-responsive reporter
sequence PG13. A tetramerization-incompetent but
DNA binding–competent mutant of  Np73 ,  Np73
L(322)P (corresponding to L371P in TAp73 ; refer-
ence 4), shows a significant but incomplete reversal of
the dominant-negative inhibition of p53 transactiva-
tion by  Np73 .777 Zaika et al.
transfected with wild-type p53 expression plasmid before
incubation with antisense or sense oligonucleotides. As al-
ready seen in Fig. 7 A, p53-expressing cells treated with
antisense oligonucleotides showed significantly enhanced
apoptosis compared with the same cells treated with sense
oligonucleotides (Fig. 7 B). To confirm that our antisense
strategy works, we determined  Np73 protein levels. As
shown in Fig. 7 C, transfection of the antisense oligonucle-
otide clearly down-regulated endogenous  Np73 protein
levels compared with the sense control oligonucleotide.
Taken together, these studies clearly indicate that endoge-
nous  Np73 exerts a significant transdominant inhibition
of p53 function. Down-regulation of endogenous  Np73
levels alleviates its suppressive action on p53-mediated
apoptosis after DNA damage.
Discussion
p53 controls a powerful stress response by integrating
signals from many types of DNA damage or inappropriate
oncogenic stimulation. Activation of p53 elicits a cellular
response of apoptosis, cell cycle arrest, or senescence,
thereby preventing tumor formation. Therefore, direct or
indirect loss of p53 function is a preeminent defect in most
human cancers whether via intragenic mutation of p53 it-
self (33), lack of p53 nuclear retention (34), loss of its up-
stream activator p14ARF (35), or inhibition by its antago-
nist HDM2 (36, 37). Here we show that the human TP73
gene, a homologue of p53, produces an NH2 terminally
truncated isoform driven by an alternative internal pro-
moter in intron 3. Human  Np73 starts with a unique
exon 3  that is highly conserved from mouse exon 3  and is
in frame with exon 4.  Np73 lacks the transactivation do-
main and is therefore predicted to function as a transdomi-
nant inhibitor of p53. In physical and functional assays, we
demonstrate dominant-negative interactions between hu-
man  Np73 and wild-type p53 or transcription-competent
TAp73.  Np73 is a potent inhibitor of wild-type p53 and
TAp73 with respect to their transcriptional activation, ap-
optotic ability, and growth suppressor function. Of note,
 Np73-mediated interference with the biological p53 re-
sponse occurs at endogenous  Np73 levels, because anti-
sense-directed down-regulation of endogenous  Np73 ex-
pression leads to a derepression of the p53 response.
Importantly, in this study we provide the first clinical ev-
idence that  Np73 is frequently up-regulated in a variety
of primary cancers including cancers of the breast and the
female genital tract. We show that tumor-specific up-regu-
lation of  Np73 occurs at the mRNA and protein level in
primary tumors. In a rigorous comparison of tumor/normal
tissue pairs from 37 patients, 73% show  Np73 up-regula-
tion specifically in their tumor tissues but not in their re-
spective normal tissues of origin. In addition, a subset of
those tumors also up-regulate the previously described
Ex2Del p73, another transdominant inhibitor of p53, but
one that is generated from the P1 promoter of TP73 via al-
ternative splicing. Taken together, 81% of tumor pairs ex-
hibited tumor-specific up-regulation of  Np73 and/or
Ex2Del p73. Of note, among the tumors with up-regula-
tion of any one or all three TP73 transcripts ( Np73,
Ex2Del p73, and TAp73), 71% exhibited preferential up-
regulation of  Np73 or Ex2Del p73. Moreover, two thirds
of the latter group of tumors showed exclusive up-regula-
tion of  Np73 and/or Ex2Del p73 without any concomi-
tant rise in TAp73. Furthermore, among tumors with pref-
erential up-regulation of  Np73 and Ex2Del p73, 71%
Figure 7. Down-regulation of endogenous  Np73 levels alleviates its
suppressive action and thereby enhances apoptosis mediated by p53 and
TAp73. (A) Wild-type p53 harboring RKO cells were transfected with
antisense (as) or sense (s) oligonucleotides (200 nM each) directed against
exon 3  of DNp73. After 8 h, cells were subjected to DNA damage by 1
mM camptothecin for an additional 16 h before TUNEL staining. Apop-
tosis was determined by measuring green fluorescence as described in Ma-
terials and Methods. Camp, cells treated with camptothecin alone. (B)
RKO cells were transfected with 360 ng wild-type p53 expression plas-
mid with 200 nM of either  Np73 antisense (as) or sense (s) oligonucle-
otides. 20 h after transfection, TUNEL staining was performed. Apoptosis
was quantitated as described above. (C) Cells were transfected with 200
nM each of antisense (as) or sense (s) oligonucleotides. 36 h later, equal
amounts of lysates (2 mg total protein) were immunoprecipitated with
ER15 and blotted with the polyclonal anti- Np73.778  Np73 Is Up-regulated in Human Tumors
harbored wild-type p53. In contrast, among the (small)
group of tumors with preferential TAp73 up-regulation,
66% harbored mutant p53. In summary, given the trend
between tumor-specific up-regulation of  Np73 and/or
Ex2Del p73 on the one hand and wild-type p53 status on
the other, it is tempting to speculate that the expression of
dominant-negative p73 isoforms alleviates the selection
pressure for p53 mutations in tumors by functionally inacti-
vating the suppressor action of p53. More tumor samples
need to be analyzed to clarify this question. If confirmed,
however, this mode of p53 inactivation would be function-
ally equivalent to the amplification of the HDM2 gene in
some human sarcomas and leukemias (36, 37). While this
work was in progress, Grob et al. (38) reported that p53
and TAp73 can directly induce  Np73 via a p53-respon-
sive element in the  Np73 promoter in cultured cells.
Moreover, Nakagawa et al. (39) confirmed that TAp73 di-
rectly transactivates  Np73, but such an activity for p53
could not be found by this group. Nevertheless, these re-
sults further fortify the analogy to the p53-HDM2 autoreg-
ulatory feedback loop. It will be interesting to determine
whether p53 and/or TAp73 itself drive the overexpression
of  Np73 in primary tumors as well.
We provide evidence that physical interaction between
 Np73  and wild-type p53 is one of the possible func-
tional mechanisms of this inhibition. We showed that this
mixed complex occurs naturally in cultured human tumor
cells and tumor tissues. While this work was under review,
Nakagawara et al. (39) also reported that  Np73   and
 Np73  form stable mixed complexes with endogenous
and ectopic wild-type p53, as well as with TAp73 . Simi-
larly, Pozniak et al. (18) reported a direct physical interac-
tion of mouse  Np73  and  Np73  proteins with mouse
wild-type p53, both of which inhibited the apoptosis-pro-
moting activity of p53. Thus, heterocomplexes appear to
interfere with the specific DNA binding activity of wild-
type p53. In contrast to  Np73, TAp73 isoforms are un-
able to form a protein complex with wild-type p53 (Fig. 5,
B and C; references 18 and 30–32). Therefore, the exist-
ence of mixed complexes suggests that the unique exon 3 
at the NH2 terminus of  Np73, in conjunction with the
missing transactivation domain, induces a conformational
change in  Np73 that allows the complex to form. In con-
trast, another recently described isoform named  TA-
p73 , which is encoded by p73 (exons 4–14) but missing
the unique exon 3 , does not appear to form a complex
with wild-type p53 (40). Heterooligomeric complexes
mirror the ability of many missense p53 mutants in het-
erozygous tumors to abrogate the function of the remain-
ing wild-type p53 allele (41, 42). Of note, a stoichiometry
as low as 1:3 of mutant to wild-type p53 molecules already
abrogates wild-type p53 function, suggesting that a similar
stoichiometry might be effective for  Np73 as well. An
additional mechanism of p53 inhibition might be direct
promoter competition, with  Np73 displacing p53 from
the DNA binding site (43). Such a phenomena has been
seen in gel shift assays with high concentrations of in vitro
translated p73 (exons 4–14) protein ( TA-p73 ; reference
40). In nuclear extracts of H1299 and U2OS cells cotrans-
fected with p53 plus  Np73, which more closely mimics
the physiological situation than in vitro translated proteins,
we also observed a decrease in p53–DNA complex forma-
tion in the presence of  Np73 , supporting the notion of
promoter competition. Under these experimental condi-
tions, however, we failed to obtain clear evidence that
 Np73  alone can directly bind to p53 cognate sites. Al-
though both inhibitory mechanisms are likely, this point
needs additional study.
Responsiveness to oncogenes and selected forms of
DNA damage might suggest a putative tumor suppressor
role of the TP73 gene analogous to TP53. However, tu-
mor-associated overexpression of (total) p73 and in some
cases TAp73 rather than loss of expression, is the most
commonly observed tumor-specific abnormality of the
TP73 gene. This fact, in conjunction with a conspicuous
lack of p73 mutation in human tumors and a lack of a can-
cer phenotype in p73-deficient mice, provides clear evi-
dence that the TP73 gene is not a classic Knudson-type
tumor suppressor in vivo. Instead, our finding that a signif-
icant percentage of human tumors specifically select for
dominant-negative p73 isoforms strongly argues for their
oncogenic role during tumorigenesis in vivo. Preferential
up-regulation of  Np73 and Ex2Del p73 in tumors might
bestow oncogenic activity upon the TP73 gene that specif-
ically interferes with the tumor suppressor functions of
wild-type p53 and TAp73. In fact, this scenario suggests
that the TP73 gene embodies the “two genes in one” idea
with products that play opposing roles within the family
circuitry. Their impact on tumor formation in vivo might
therefore depend on the balance between tumor-promot-
ing and -suppressing family members. The existence of this
inhibitory family network might explain the paucity of p73
mutations in human tumors. In the developing mouse
brain,   Np73 is the predominant form of TP73 and a
powerful inhibitor of p53 (18). In vivo and in vitro studies
showed that  Np73 plays an essential antiapoptotic role re-
quired to counteract p53-mediated neuronal death during
the “sculpting” of the developing brain. This explains why
p73 /  mice, missing all forms of p73 including protective
 Np73, underwent accelerated neuronal death in sympa-
thetic ganglia (18). Thus, in keeping with a common
theme in cancer, a developmental inhibitory network that
is essential for normal physiology resurfaces in cancer, but
in a corrupted and derailed fashion. In support of the idea
that  Np73 can act as an oncogene in vivo, overexpression
of  N isoforms of p63, a p73 homologue, is found in hu-
man cancers including lung cancer, squamous cell carci-
noma of the head and neck (44), bladder cancer (45), and
nasopharyngeal carcinoma (46). Importantly, a specific
 Np63 isoform is oncogenic in nude mice and in the Rat
1a focus formation assay (44).
Evidence from some human cancers and mouse models
indicates that the mutational status of p53 is an important
clinical variable for prognosis as well as for guiding the ag-
gressiveness of anticancer therapy. However, currently, p53
mutational status is not widely accepted as a clinical indica-779 Zaika et al.
tor because many studies show that its prognostic power for
survival and its predictive value for therapeutic response is
poor (for review see reference 47). From a practical stand-
point, the discovery of a  Np73-based p53–p73 interfer-
ence network suggests that the p53 status of a tumor should
no longer be considered in isolation. The existence of this
inhibitory network might account for the inconsistencies of
clinical studies that sought to use p53 status as a predictor of
outcome. It mandates that we do a careful analysis of the
functional consequences of this network in vivo. The es-
tablishment and clarification of an inhibitory p53–p73 net-
work would have a major clinical impact ranging from fine
tuning the prognostic power of p53 mutation status to ra-
tional p53–p73-targeted drug design.
In conclusion, we report here the cloning of human
 Np73 and show that  Np73 mediates a novel inactivation
mechanism of wild-type p53 and TAp73 via dominant-
negative interference. Deregulated expression of  Np73
can bestow oncogenic activity upon the TP73 gene by
functionally inactivating the suppressor action of p53 and
TAp73. This trait might be frequently selected for in a va-
riety of human cancers.
We thank T. Shirangi for technical assistance.
This study is supported by grants from the National Cancer In-
stitute and the United States Army Medical Research Command.
Submitted: 1 February 2002
Revised: 24 June 2002
Accepted: 18 July 2002
References
1. Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J.C. Biscan,
A. Valent, A. Minty, P. Chalon, J.M. Lelias, X. Dumont, et
al. 1997. Monoallelically expressed gene related to p53 at
1p36, a region frequently deleted in neuroblastoma and other
human cancers. Cell. 90:809–819.
2. Jost, C.A., M.C. Marin, and W.G. Kaelin, Jr. 1997. p73 is a
simian p53-related protein that can induce apoptosis. Nature.
389:191–194.
3. Zhu, J., J. Jiang, W. Zhou, and X. Chen. 1998. The potential
tumor suppressor p73 differentially regulates cellular p53 tar-
get genes. Cancer Res. 58:5061–5065.
4. Zaika, A., M. Irwin, C. Sansome, and U.M. Moll. 2001. On-
cogenes induce and activate endogenous p73 protein. J. Biol.
Chem. 276:11310–11316.
5. Irwin, M., M.C. Marin, A.C. Phillips, R.S. Seelan, D.I.
Smith, W. Liu, E.R. Flores, K.Y. Tsai, T. Jacks, K.H. Vous-
den, et al. 2000. Role for the p53 homologue p73 in E2F-1-
induced apoptosis. Nature. 407:645–648.
6. Lissy, N.A., P.K. Davis, M. Irwin, W.G. Kaelin, and S.F.
Dowdy. 2000. A common E2F-1 and p73 pathway mediates
cell death induced by TCR activation. Nature. 407:642–645.
7. Stiewe, T., and B.M. Putzer. 2000. Role of the p53-homo-
logue p73 in E2F1-induced apoptosis. Nat. Genet. 26:464–
469.
8. Gong, J.G., A. Costanzo, H.Q. Yang, G. Melino, W.G. Kae-
lin, Jr., M. Levrero, and J.Y. Wang. 1999. The tyrosine ki-
nase c-Abl regulates p73 in apoptotic response to cisplatin-in-
duced DNA damage. Nature. 399:806–809.
9. Yuan, Z.M., H. Shioya, T. Ishiko, X. Sun, J.Gu, Y.Y.
Huang, H. Lu, S. Kharbanda, R. Weichselbaum, and D.
Kufe. 1999. p73 is regulated by tyrosine kinase c-Abl in the
apoptotic response to DNA damage. Nature. 399:814–817.
10. Agami, R., G. Blandino, M. Oren, and Y. Shaul. 1999. In-
teraction of c-Abl and p73alpha and their collaboration to in-
duce apoptosis. Nature. 399:809–813.
11. Costanzo, A., P. Merlo, N. Pediconi, M. Fulco, V. Sartorelli,
P.A. Cole, G. Fontemaggi, M. Fanciulli, L. Schiltz, G. Blan-
dino, et al. 2002. DNA damage-dependent acetylation of p73
dictates the selective activation of apoptotic target genes. Mol.
Cell. 9:175–186.
12. Yamasaki, L., T. Jacks, R. Bronson, E. Goillot, E. Harlow,
and N.J. Dyson. 1996. Tumor induction and tissue atrophy
in mice lacking E2F-1. Cell. 85:537–548.
13. Field, S.J., F.Y. Tsai, F. Kuo, A.M. Zubiaga, W.G. Kaelin,
Jr., D.M. Livingston, S.H. Orkin, and M.E. Greenberg.
1996. E2F-1 functions in mice to promote apoptosis and sup-
press proliferation. Cell. 85:549–561.
14. Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Ooster-
wegel, J. Bonnin, C. Vagner, H. Bonnet, P. Dikkes, A.
Sharpe, et al. 2000. p73-deficient mice have neurological,
pheromonal and inflammatory defects but lack spontaneous
tumours. Nature. 404:99–103.
15. Moll, U.M., S. Erster, and A. Zaika. 2001. p53, p63 and p73
- solos, alliances and feuds among family members. Biochim.
Biophys. Acta. 1552:47–59.
16. Kovalev, S., N.D. Marchenko, S. Swendeman, M. LaQuag-
lia, and U.M. Moll. 1998. Expression level, allelic origin, and
mutation analysis of the p73 gene in neuroblastoma tumors
and cell lines. Cell Growth Differ. 9:897–903.
17. Zaika, A.I., S. Kovalev, N.D. Marchenko, and U.M. Moll.
1999. Overexpression of the wild type p73 gene in breast
cancer tissues and cell lines. Cancer Res. 59:3257–3263.
18. Pozniak, C.D., S. Radinovic, A. Yang, F. McKeon, D.R.
Kaplan, and F.D. Miller. 2000. An anti-apoptotic role for the
p53 family member, p73, during developmental neuron
death. Science. 289:304–306.
19. Marchenko, N.D., A.I. Zaika, and U.M. Moll. 2000. Death
signal induced localization of p53 protein to mitochondria: a
potential role in apoptotic signaling. J. Biol. Chem. 275:
16202–16212.
20. Baker, S.J., S. Markowitz, E.R. Fearon, J.K. Willson, and B.
Vogelstein. 1990. Suppression of human colorectal carci-
noma cell growth by wild type p53. Science. 249:912–915.
21. Ostermeyer, A.G., E. Runko, B. Winkfield, B. Ahn, and
U.M. Moll. 1996. Cytoplasmically sequestered wild-type p53
protein in neuroblastoma is relocated to the nucleus by a
C-terminal peptide. Proc. Natl. Acad. Sci. USA. 93:15190–
15194.
22. Ng, S.W., G.K. Yiu, Y. Liu, L.W. Huang, M. Palnati, S.H.
Jun, R.S. Berkowitz, and S.C. Mok. 2000. Analysis of p73 in
human borderline and invasive ovarian tumor. Oncogene. 19:
1885–1890.
23. Fillippovich, I., N. Sorokina, M. Gatei, Y. Haupt, K. Hob-
son, E. Moallem, K. Spring, M. Mould, M.A. McGuckin,
M.F. Lavin, et al. 2002. Transactivation-deficient p73alpha
(p73Deltaexon2) inhibits apoptosis and competes with p53.
Oncogene. 20:514–522.
24. O’Nions, J., L.A. Brooks, A. Sullivan, A. Bell, B. Dunne, M.
Rozycka, A. Reddy, J.A. Tidy, D. Evans, P.J. Farrell, et al.
2001. p73 is over-expressed in vulval cancer principally as the
Delta2 isoform. Br. J. Cancer. 85:1551–1556.780  Np73 Is Up-regulated in Human Tumors
25. IARC p53 Database. http://www.iarc.fr/p53/Index.html.
26. Diller, L., J. Kassel, C.E. Nelson, M.A. Gryka, G. Litwak, M.
Gebhardt, B. Bressac, M. Ozturk, S.J. Baker, B. Vogelstein,
et al. 1990. p53 functions as a cell cycle control protein in os-
teosarcomas. Mol. Cell. Biol. 10:5772–5781.
27. Pietenpol, J.A., T. Tokino, S. Thiagalingam, W.S. el-Deiry,
K.W. Kinzler, and B. Vogelstein. 1994. Sequence-specific
transcriptional activation is essential for growth suppression
by p53. Proc. Natl. Acad. Sci. USA. 91:1998–2002.
28. Finlay, C.A., P.W. Hinds, and A.J. Levine. 1989. The p53
proto-oncogene can act as a suppressor of transformation.
Cell. 57:1083–1093.
29. Zhu, J., S. Nozell, J. Wang, J. Jiang, W. Zhou, and X. Chen.
2001. p73 cooperates with DNA damage agents to induce
apoptosis in MCF7 cells in a p53-dependent manner. Onco-
gene. 20:4050–4057.
30. Marin, M.C., C.A. Jost, L.A. Brooks, M.S. Irwin, J.
O’Nions, J.A Tidy, N. James, J.M. McGregor, C.A. Har-
wood, I.G. Yulug, et al. 2000. A common polymorphism
acts as an intragenic modifier of mutant p53 behaviour. Na-
ture Genet. 25:47–54.
31. Di Como, C.J., C. Gaiddon, and C. Prives. 1999. p73 func-
tion is inhibited by tumor-derived p53 mutants in mamma-
lian cells. Mol. Cell. Biol. 19:1438–1449.
32. Gu, J., D. Chen, J. Rosenblum, R.M. Rubin, and Z.M.
Yuan. 2000. Identification of a sequence element from p53
that signals for Mdm2-targeted degradation. Mol. Cell. Biol.
20:1243–1253.
33. Vogelstein, B., D. Lane, and A.J. Levine. 2000. Surfing the
p53 network. Nature. 408:307–310.
34. Moll, U.M., M. LaQuaglia, J. Benard, and G. Riou. 1995.
Wild-type p53 protein undergoes cytoplasmic sequestration
in undifferentiated neuroblastomas but not in differentiated
tumors. Proc. Natl. Acad. Sci. USA. 92:4407–4411.
35. Sherr, C.J. 1998. Tumor surveillance via the ARF-p53 path-
way. Genes Dev. 12:2984–2991.
36. Oliner, J.D., J.A. Pietenpol, S. Thiagalingam, J. Gyuris,
K.W. Kinzler, and B. Vogelstein. 1993. Oncoprotein
MDM2 conceals the activation domain of tumor suppressor
p53. Nature. 362:857–860.
37. Watanabe, T., A. Ichikawa, H. Saito, and T. Hotta. 1996.
Overexpression of the MDM2 oncogene in leukemia and
lymphoma. Leuk. Lymphoma. 21:391–397.
38. Grob, T.J., U. Novak, C. Maisse, D. Barcaroli, A.U. Luthi,
F. Pirnia, B. Hugli, H.U. Graber, V. De Laurenzi, M.F. Fey,
et al. 2001. Human DeltaNp73 regulates a dominant negative
feedback loop for TAp73 and p53. Cell Death Differ. 8:1213–
1223.
39. Nakagawa, T., M. Takahashi, T. Ozaki, K. Watanabe, S.
Todo, H. Mizuguchi, T. Hayakawa, and A. Nakagawara.
2002. Autoinhibitory regulation of p73 by  Np73 to modu-
late cell survival and death through a p73-specific target ele-
ment within the  Np73 promoter. Mol. Cell. Biol. 22:2575–
2585.
40. Stiewe, T., C.C. Theseling, and B.M. Putzer. 2002. Transac-
tivation-deficient  TA-p73 inhibits p53 by direct competi-
tion for DNA binding. J. Biol. Chem. 277:14177–14185.
41. Kern, S.E., J.A. Pietenpol, S. Thiagalingam, A. Seymour,
K.W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of
p53 inhibit p53-regulated gene expression. Science. 256:827–
830.
42. Unger, T., M.M. Nau, S. Segal, and J.D. Minna. 1992. p53:
a transdominant regulator of transcription whose function is
ablated by mutations occurring in human cancer. EMBO J.
11:1383–1390.
43. Ishimoto, O., C. Kawahara, K. Enjo, M. Obinata, T.
Nukiwa, and S. Ikawa. 2002. Possible oncogenic potential of
DeltaNp73: a newly identified isoform of human p73. Cancer
Res. 62:636–641.
44. Hibi, K., B. Trink, M. Patturajan, W.H. Westra, O.L. Cabal-
lero, D.E. Hill, E.A. Ratovitski, J. Jen, and D. Sidransky.
2000. AIS is an oncogene amplified in squamous cell carci-
noma. Proc. Natl. Acad. Sci. USA. 97:5462–5467.
45. Park, B.J., S.J. Lee, J.I. Kim, S.J. Lee, C.H. Lee, S.G. Chang,
J.H. Park, and S.G. Chi. 2000. Frequent alteration of p63 ex-
pression in human primary bladder carcinomas. Cancer Res.
60:3370–3374.
46. Crook, T., J.M. Nicholl, J. Brooks, J. O’Nions, and M.J. All-
day. 2000. High level expression of deltaN-p63: a mechanism
for the inactivation of p53 in undifferentiated nasopharyngeal
carcinoma (NPC)? Oncogene. 10:3439–3444.
47. Moll, U.M. 2000. New p53-based strategies for cancer ther-
apy. In DNA Alterations in Cancer: Genetic and Epigenetic
Changes. M. Ehrlich, editor. Eaton Publishing, Natick, MA.
439–455.